Cancer
01 Jan 2013
IEV and autologous peripheral blood progenitor cell transplant salvage treatment for lymphoid malignancies
Primary endpoints were to confirm the feasibility and efficacy of IEV in poor risk Hodgkin’s lymphoma and aggressive NHLs. Additional endpoints were to try to evaluate its possible role in the salvage strategy of indolent NHLs, lymphoblastic lymphoma and multiple myeloma. Analysis of toxicity and PBSC mobilization. Conclusions…
Cancer
01 Jan 2013
Head and Neck Phase III Iressa Vs Methotrexate Refractory. Iressa Vs Methotrexate (IMEX)
Purpose- This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival. Official Title A Phase III Randomised, Stratified, Parallel-Group, Mulit-Centre, Comparative Study of ZD1839 (Iressa) 250 mg and 500 mg Versus Methotraxate for Previously Treated Patients with Squamous Cell…
Cancer
01 Jan 2013
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Rationale: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer. Purpose: This randomized…
Cancer
01 Jan 2013
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as tirapazamine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Tirapazamine may help cisplatin kill more tumor cells by making tumor cells more sensitive to the drug. Radiation…
Cancer
01 Jan 2013
Brain Metastases Study
Purpose- Comparison of radiotherapy fractionation schemes for brain metastasis. Official Title To Determine Which of Two Radiotherapy Brain Fractionation Schemes is Superior in the Treatment of Brain Metastases Conditions Study Type Interventional Study Design Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Efficacy Study Further Details Primary Outcomes: Control of…
Cancer
01 Jan 2013
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin’s Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy using cyclosporine, interferon gamma, and…
Bone
01 Jan 2013
A Phase I/II Study of PBPC Mobilisation with VTP195183 Plus G-CSF Compared to Mobilisation with G-CSF Alone
Hematopoietic stem cells (HSC) are used to support the administration of high dose chemotherapy for a range of human cancers. For a safe HSC transplantation, a minimum of 5 million HSC per kilogram are required. HSC are collected from the bone marrow by using drugs such as G-CSF (filgrastim) which…
Cancer
01 Jan 2013
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable to complete surgical resection. The Firm-ACT trial is the first ever conducted…
Cancer
01 Jan 2013
Combination Chemotherapy After Surgery in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective after surgery in treating breast cancer. PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens…
